论文部分内容阅读
目的探讨14-3-3蛋白在星形细胞瘤中的表达与肿瘤病理分级和预后间的关系。方法采用免疫组化ABC法检测10例正常脑组织和67例确诊并有随访的人脑星形细胞瘤石蜡标本中14-3-3蛋白的表达情况。分析14-3-3蛋白的表达与肿瘤恶性程度及预后间的关系。结果在正常脑组织标本中,14-3-3蛋白主要表达于神经元胞体和突起,而在少数的胶质细胞中仅见其弱表达。绝大部分星形胶质细胞瘤中可见14-3-3蛋白阳性表达,其阳性表达率为:II级76.5%(13/17),III级76.2%(16/21),IV级79.3%(23/29)。不同恶性级别的星形细胞肿瘤中,14-3-3蛋白的阳性表达率无显著差别(P>0.05),但14-3-3蛋白表达的强度和范围有随肿瘤的恶性度增高而增加的趋势(P<0.05)。52例14-3-3蛋白阳性表达患者的生存期明显短于15例14-3-3蛋白表达阴性的患者(P<0.01)。结论14-3-3蛋白在人脑星形细胞瘤中的表达上调与肿瘤的恶性程度及预后相关。14-3-3蛋白有望成为星形细胞瘤基因治疗的新靶点。
Objective To investigate the relationship between the expression of 14-3-3 protein and the pathological grade and prognosis of astrocytomas. Methods Immunohistochemical ABC method was used to detect the expression of 14-3-3 protein in 10 normal brain tissues and 67 paraffin-embedded specimens of human astrocytoma confirmed and followed up. The relationship between the expression of 14-3-3 protein and the degree of malignancy and prognosis was analyzed. Results In normal brain tissue samples, 14-3-3 protein was mainly expressed in neuronal somatic cells and protrusions, whereas in a few glial cells, only weak expression was observed. The majority of astrocytomas showed positive expression of 14-3-3 protein, with a positive rate of 76.5% (13/17) in grade II, 76.2% (16/21) in grade III and 79.3% in grade IV (23/29). The positive rates of 14-3-3 protein in astrocytic tumors of different malignant grades were not significantly different (P> 0.05). However, the intensity and the range of 14-3-3 protein expression increased with the malignant degree of tumors Trend (P <0.05). The survival time of 52 patients with 14-3-3 protein expression was significantly shorter than that of 15 patients with 14-3-3 protein expression (P <0.01). Conclusion The up-regulation of 14-3-3 protein in human brain astrocytoma correlates with the malignant degree and prognosis of the tumor. 14-3-3 protein is expected to become a new target for gene therapy of astrocytoma.